215 related articles for article (PubMed ID: 30677777)
41. Growth potential of prolactinomas in men: is it really different from women?
Nishioka H; Haraoka J; Akada K
Surg Neurol; 2003 May; 59(5):386-90; discussion 390-1. PubMed ID: 12765811
[TBL] [Abstract][Full Text] [Related]
42. Current approach to treatments for prolactinomas.
Tirosh A; Shimon I
Minerva Endocrinol; 2016 Sep; 41(3):316-23. PubMed ID: 26399371
[TBL] [Abstract][Full Text] [Related]
43. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas.
Williams JC; Stone D; Smith-Arica JR; Morris ID; Lowenstein PR; Castro MG
Mol Ther; 2001 Dec; 4(6):593-602. PubMed ID: 11735344
[TBL] [Abstract][Full Text] [Related]
44. Occurrence of extensive spherical amyloid deposits in a prolactin-secreting pituitary macroadenoma: a radiologic-pathologic correlation.
Levine SN; Ishaq S; Nanda A; Wilson JD; Gonzalez-Toledo E
Ann Diagn Pathol; 2013 Aug; 17(4):361-6. PubMed ID: 23602507
[TBL] [Abstract][Full Text] [Related]
45. Transnasal surgery for prolactin-secreting pituitary adenomas in childhood and adolescence.
Abe T; Lüdecke DK
Surg Neurol; 2002 Jun; 57(6):369-78; discussion 378-9. PubMed ID: 12176193
[TBL] [Abstract][Full Text] [Related]
46. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
[TBL] [Abstract][Full Text] [Related]
47. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.
Raverot G; Wierinckx A; Dantony E; Auger C; Chapas G; Villeneuve L; Brue T; Figarella-Branger D; Roy P; Jouanneau E; Jan M; Lachuer J; Trouillas J;
J Clin Endocrinol Metab; 2010 Apr; 95(4):1708-16. PubMed ID: 20164287
[TBL] [Abstract][Full Text] [Related]
48. Role of matrix metalloproteinase 9 in pituitary tumor behavior.
Turner HE; Nagy Z; Esiri MM; Harris AL; Wass JA
J Clin Endocrinol Metab; 2000 Aug; 85(8):2931-5. PubMed ID: 10946906
[TBL] [Abstract][Full Text] [Related]
49. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
[TBL] [Abstract][Full Text] [Related]
50. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness.
Shimon I; Hinton DR; Weiss MH; Melmed S
Clin Endocrinol (Oxf); 1998 Jan; 48(1):23-9. PubMed ID: 9509064
[TBL] [Abstract][Full Text] [Related]
51. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
52. The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.
Roof AK; Jirawatnotai S; Trudeau T; Kuzyk C; Wierman ME; Kiyokawa H; Gutierrez-Hartmann A
Endocrinology; 2018 Jun; 159(6):2421-2434. PubMed ID: 29726995
[TBL] [Abstract][Full Text] [Related]
53. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
54. Malignant prolactinoma with multiple bone and pulmonary metastases. Case report.
Lamas C; Núñez R; García-Uría J; Salas C; Saucedo G; Estrada J; Parajón A; Lucas T
J Neurosurg; 2004 Aug; 101(1 Suppl):116-21. PubMed ID: 16206983
[TBL] [Abstract][Full Text] [Related]
55. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
56. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
57. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
58. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
[TBL] [Abstract][Full Text] [Related]
59. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.
Coopmans EC; van Meyel SWF; Pieterman KJ; van Ipenburg JA; Hofland LJ; Donga E; Daly AF; Beckers A; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2019 Aug; 181(2):K21-K27. PubMed ID: 31167168
[TBL] [Abstract][Full Text] [Related]
60. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.
Wierinckx A; Auger C; Devauchelle P; Reynaud A; Chevallier P; Jan M; Perrin G; Fèvre-Montange M; Rey C; Figarella-Branger D; Raverot G; Belin MF; Lachuer J; Trouillas J
Endocr Relat Cancer; 2007 Sep; 14(3):887-900. PubMed ID: 17914117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]